400 Spectrum Center Drive
Suite 2040
Irvine, CA 92618
United States
(949) 409-3700
https://cgoncology.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 61
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Arthur Kuan | Chairman & CEO | 640.97k | N/A | 1991 |
Mr. Ambaw Bellete M.S. | President & COO | 1.06M | N/A | 1971 |
Dr. Vijay Kasturi M.D. | Chief Medical Officer | 212.24k | N/A | 1968 |
Ms. Corleen M. Roche | CFO & Secretary | N/A | N/A | 1967 |
Ms. Amy Steele | Vice President of Finance, Accounting & Administration | N/A | N/A | N/A |
Mr. Swapnil Bhargava Ph.D. | Chief Technical Officer | N/A | N/A | N/A |
Mr. Bing Kung | Vice President of Corporate Development | N/A | N/A | N/A |
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
CG Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.